These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 23837575)

  • 21. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
    Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
    Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic interaction between 17-AAG and phosphatidylinositol 3-kinase inhibition in human malignant glioma cells.
    Premkumar DR; Arnold B; Jane EP; Pollack IF
    Mol Carcinog; 2006 Jan; 45(1):47-59. PubMed ID: 16267832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
    Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
    Takeuchi H; Kondo Y; Fujiwara K; Kanzawa T; Aoki H; Mills GB; Kondo S
    Cancer Res; 2005 Apr; 65(8):3336-46. PubMed ID: 15833867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
    Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced anti-cancer effect of a phosphatidylinositol-3 kinase inhibitor and doxorubicin on human breast epithelial cell lines with different p53 and oestrogen receptor status.
    Wang YA; Johnson SK; Brown BL; McCarragher LM; Al-Sakkaf K; Royds JA; Dobson PR
    Int J Cancer; 2008 Oct; 123(7):1536-44. PubMed ID: 18634052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination of a novel HDAC inhibitor OBP-801/YM753 and a PI3K inhibitor LY294002 synergistically induces apoptosis in human endometrial carcinoma cells due to increase of Bim with accumulation of ROS.
    Yoshioka T; Yogosawa S; Yamada T; Kitawaki J; Sakai T
    Gynecol Oncol; 2013 May; 129(2):425-32. PubMed ID: 23403163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
    Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
    Chen P; Wen X; Wang B; Hou D; Zou H; Yuan Q; Yang H; Xie J; Huang H
    Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Apoptosis induction of human leukemia cells by Streptomyces sp. SY-103 metabolites through activation of caspase-3 and inactivation of Akt.
    Jeong SY; Han MH; Jin CY; Kim GY; Choi BT; Nam TJ; Kim SK; Choi YH
    Int J Mol Med; 2010 Jan; 25(1):31-40. PubMed ID: 19956899
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway.
    Surmeli Z; Gursoy P; Erdogan AP; Bozkurt E; Atmaca H; Uzunoglu S; Sezgin C; Şanlı UA; Uslu R; Karaca B
    Tumour Biol; 2016 Mar; 37(3):3665-73. PubMed ID: 26462835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
    Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
    Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1α pathway.
    Xu R; Zhang Y; Li A; Ma Y; Cai W; Song L; Xie Y; Zhou S; Cao W; Tang X
    Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 33982772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells.
    Lane D; Robert V; Grondin R; Rancourt C; Piché A
    Int J Cancer; 2007 Sep; 121(6):1227-37. PubMed ID: 17534891
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific inhibitor of phosphatidylinositol 3'-kinase, in human colon cancer cells.
    Semba S; Itoh N; Ito M; Harada M; Yamakawa M
    Clin Cancer Res; 2002 Jun; 8(6):1957-63. PubMed ID: 12060641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance.
    Barancík M; Bohácová V; Sedlák J; Sulová Z; Breier A
    Eur J Pharm Sci; 2006 Dec; 29(5):426-34. PubMed ID: 17010577
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells.
    Uddin S; Hussain AR; Al-Hussein KA; Manogaran PS; Wickrema A; Gutierrez MI; Bhatia KG
    Clin Cancer Res; 2005 Apr; 11(8):3102-8. PubMed ID: 15837766
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic efficacy of hydrogen‑rich saline alone and in combination with PI3K inhibitor in non‑small cell lung cancer.
    Jiang Y; Liu G; Zhang L; Cheng S; Luo C; Liao Y; Guo S
    Mol Med Rep; 2018 Aug; 18(2):2182-2190. PubMed ID: 29901139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The PI3K/Akt inhibitor LY294002 reverses BCRP-mediated drug resistance without affecting BCRP translocation.
    Imai Y; Yoshimori M; Fukuda K; Yamagishi H; Ueda Y
    Oncol Rep; 2012 Jun; 27(6):1703-9. PubMed ID: 22426819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas.
    Van Meter TE; Broaddus WC; Cash D; Fillmore H
    Cancer; 2006 Nov; 107(10):2446-54. PubMed ID: 17041888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.